HER2-Negative Breast Carcinoma — Trials

HER2-Negative Breast Carcinoma — Trials · CancerIndex

Clinical trials

Registered studies

43 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 29
Recruiting: 21
Ph III recruiting: 3
Growth YoY: —
Industry share: 10%
Top sponsor: National Cancer Institute (NCI)
Termination share: —

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (9)

clinicaltrialsPublishedShowing 1–6 of 6 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT07136493	Circulating Tumor DNA Based Minimal Residual Disease Detection for Patients With Early-Stage Breast Cancer	withdrawn	N/A	0	City of Hope Medical CenterOTHER	1	Jun 25, 2026	clinicaltrials
NCT06590558	Testing the Addition of an Investigational Anti-Cancer Drug, ASTX660 (Tolinapant), to a Usual Chemotherapy Treatment (Eribulin) for Treatment of Advanced Triple Negative Breast Cancer	withdrawn	Phase 1	0	National Cancer Institute (NCI)NIH	0	Jul 3, 2025